2024
2024-04-23
STOCKHOLM, April 23[rd], 2024, Moberg Pharma AB (OMX:MOB) reports strong interest from pharmacists, physicians and end customers in the launch of MOB-015 under the brand Terclara[®] in Sweden. A majority of Swedish pharmacies now have the product available on the shelf.
2024-04-12
Shareholders in Moberg Pharma AB (publ), reg. no. 556697-7426, (the “Company”) are hereby convened to the Annual General Meeting on 14 May 2024 at 14:00 at Advokatfirman Schjødt, Hamngatan 27 in Stockholm.
2024-04-12
Moberg Pharma´s Annual report for 2023 has been published and is available on www.mobergpharma.se
2024-04-08
STOCKHOLM, April 8[th], 2024, Moberg Pharma AB (OMX:MOB) has submitted an application to include the proposed terbinafine supplier in the company's registration dossier for its nail fungus drug MOB-015. Approval is expected before the end of the year.
2024-02-19
STOCKHOLM, February 19[th], 2024. Moberg Pharma AB (OMX: MOB) announces that the company’s Nomination Committee has decided to present the following proposal to the Annual General Meeting 2024.
2024-02-07
STOCKHOLM, February 7[th], 2024, Moberg Pharma ABs (OMX: MOB) marker partner in Sweden – Allderma AB, a company which specialises in the sale of over-the-counter (OTC) pharmaceuticals – has now launched sales of MOB-015 under the Terclara[®] brand. The interest among pharmacies has been significant for Moberg Pharma's medication against nail fungus.